The impact of the vitamin D in neurological diseases and neurorehabilitation: From demencia to multiple sclerosis. Part I: The role of the vitamin D in the prevetion and treatment of multiple sclerosis;A D-vitamin jelento{combining double acute accent}sége neurológiai kórképekben és a neurorehabilitá cióban: A dementiától a sclerosis multiplexig: I. Rész: A D-vitamin szerepe a sclerosis multiplex megelozésé ben és kiegészíto kezelésében

Ideggyogyaszati Szemle

Volumn 66, Issue 9-10, 2013, Pages 293-303

  Speer, Gábor ^a,b  

^a Budai Irgalmasrendi Kórház ^*  (Hungary)

^b Pálmai Med Egészségügyi Központ ^*  (Hungary)

Author keywords

Epidemiology; Multiple sclerosis; Prevention; Treatment; Vitamin D

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; VITAMIN D; IMMUNOLOGIC FACTOR; VITAMIN;

ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMENTIA; ENVIRONMENTAL FACTOR; HUMAN; INCIDENCE; MULTIPLE SCLEROSIS; RISK FACTOR; TH17 CELL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED; COMPLICATION; DIET SUPPLEMENTATION; DRUG ADMINISTRATION; FEMALE; HYPERCALCEMIA; IMMUNOLOGY; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS; SUNLIGHT; CHEMICALLY INDUCED DISORDER; PREGNANCY COMPLICATION; REVIEW;

DEMENTIA; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERCALCEMIA; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; SUNLIGHT; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84887846008     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Csépány T. A sclerosis multiplex kezelése napjainkban. LAM 2011;21:97-103.
2. Speer G. A hazai D-vitamin-hiány okai és következményei: ideje felszámolni. Háziorvosi Továbbképzo{combining double acute accent} Szemle 2005; 10:760-3.
3. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol 2000;39:57-106. (Pubitemid 30480792)
4. Chen TC, Chimeh F, Lu Z, Mathieu J, Person KS, Zhang A, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007;460:213-7. (Pubitemid 46613793)
5. Datta P, Bogh MK, Olsen P, Eriksen P, Schmedes AV, Grage MM, et al. Increase in serum 25-hydroxyvitamin-D3 in humans after solar exposure under natural conditions compared to artificial UVB exposure of hands and face. Photochem Photobiol Sci 2012;11:1817-24.
6. Speer G. A D-nap. A D-vitamin helye a daganatprevencióban és a kiegészito{combining double acute accent} kezelésben. Magyar Onkológia 2010;54:303-14.
7. Bogh MK. Vitamin D production after UVB: aspects of UV-related and personal factors. Scand J Clin Lab Invest Suppl 2012;243:24-31.
8. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8.
9. Dobnig H. A review of the health consequences of the vitamin D deficiency pandemic. J Neurol Sci 2011;311: 15-8.
10. Li Z, Chen L, Niu X, Liu J, Ping M, Li R, et al. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 2012;250:9-17.
11. Smolders J, Moen SM, Damoiseaux J, Huitinga I, Holmøy T. Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci 2011;311:37-43.
12. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012;25:246-51.
13. Jankosky C, Deussing E, Gibson RL, Haverkos HW. Viruses anD-vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis. Virus Res 2012;163:424-30.
14. Nolan D, Castley A, Tschochner M, James I, Qiu W, Sayer D, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012;79:538-46.
15. Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:1170-3.
16. Ascherio A, Marrie RA. Vitamin D in MS: a vitamin for 4 seasons. Neurology 201217;79:208-10.
17. Miller AE. Multiple sclerosis: where will we be in 2020? Mt Sinai J Med 2011;78:268-79.
18. Munger KL, Ascherio A. Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler 2011;17: 1405-11.
19. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012;79:2140-5.
20. D'hooghe MB, Haentjens P, Nagels G, Garmyn M, De Keyser J. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. Mult Scler 2012;18:451-9.
21. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-40.
22. Weinstock-Guttman B, Mehta BK, Ramanathan M, Karmon Y, Henson LJ, Halper J, et al. Vitamin D and multiple sclerosis. Neurologist 2012;18:179-83.
23. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261-6.
24. Correale J, Ysrraelit MC, Gaitán MI. Vitamin D-mediated immune regulation in multiple sclerosis. J Neurol Sci 2011;311:23-31.
25. Holmøy T, Lossius A, Gundersen TE, Moen SM, Castellazzi M, Fainardi E, et al. Intrathecal levels of vitamin D and IgG in multiple sclerosis. Acta Neurol Scand 2012;125:e28-31.
26. Simon KC, Munger KL, Ascherio A. XVI European Charcot Foundation lecture: nutrition and environment: can MS be prevented? J Neurol Sci 2011;311:1-8.
27. Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-71.
28. Stewart N, Simpson S Jr, van der Mei I, Ponsonby AL, Blizzard L, Dwyer T, et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254-60.
29. Zamvil SS, Steinman L. Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right. Lancet Neurol 2011;10:672-3.
30. Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnar̊ BT, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology 2012;79:267-73.
31. Takács I, Benko{combining double acute accent} I, Toldy E, Wikonkál N, Szekeres L, Bodolay E, et al. Hazai konszenzus a D-vitamin szerepéro{combining double acute accent}l a betegségek megelo{combining double acute accent}zésében és kezelésében. Orv Hetil 2012;153(Suppl):5-26.
32. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
33. Dörr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012;13:5.
34. Correale J. If I had clinically isolated syndrome with magnetic resonance imaging diagnostic of multiple sclerosis, I would take vitamin D 10,000 IU daily: Yes. Mult Scler 2013;19:137-9.
35. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2010;(12):CD008422.
36. Mesliniene S, Ramrattan L, Giddings S, Sheikh-Ali M. Role of vitamin D in the onset, progression, and severity of multiple sclerosis. Endocr Pract 2013;19:129-36.